[go: up one dir, main page]

LT3555097T - Imidazo[4,5-d]pirolo[2,3-b]piridino junginiai kaip janus kinazės inhibitoriai - Google Patents

Imidazo[4,5-d]pirolo[2,3-b]piridino junginiai kaip janus kinazės inhibitoriai

Info

Publication number
LT3555097T
LT3555097T LTEPPCT/US2017/066744T LT17066744T LT3555097T LT 3555097 T LT3555097 T LT 3555097T LT 17066744 T LT17066744 T LT 17066744T LT 3555097 T LT3555097 T LT 3555097T
Authority
LT
Lithuania
Prior art keywords
pyrolo
imidazo
kinase inhibitors
pyridine compounds
janus kinase
Prior art date
Application number
LTEPPCT/US2017/066744T
Other languages
English (en)
Inventor
Tatiana KOUDRIAKOVA
Kevin D. Kreutter
Kristi Leonard
Michele C. Rizzolio
Russell C. Smith
Mark S. Tichenor
Aihua Wang
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of LT3555097T publication Critical patent/LT3555097T/lt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
LTEPPCT/US2017/066744T 2016-12-16 2017-12-15 Imidazo[4,5-d]pirolo[2,3-b]piridino junginiai kaip janus kinazės inhibitoriai LT3555097T (lt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662435609P 2016-12-16 2016-12-16
US201762592680P 2017-11-30 2017-11-30
US201762596607P 2017-12-08 2017-12-08
PCT/US2017/066744 WO2018112379A1 (en) 2016-12-16 2017-12-15 Small molecule inhibitors of the jak family of kinases

Publications (1)

Publication Number Publication Date
LT3555097T true LT3555097T (lt) 2022-08-25

Family

ID=61692222

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEPPCT/US2017/066744T LT3555097T (lt) 2016-12-16 2017-12-15 Imidazo[4,5-d]pirolo[2,3-b]piridino junginiai kaip janus kinazės inhibitoriai

Country Status (35)

Country Link
US (5) US10294226B2 (lt)
EP (2) EP4086256A1 (lt)
JP (2) JP7291077B2 (lt)
KR (1) KR102352462B1 (lt)
CN (1) CN110088105B (lt)
AU (3) AU2017377069B2 (lt)
CL (1) CL2019001626A1 (lt)
CO (1) CO2019006200A2 (lt)
CR (1) CR20190282A (lt)
CY (1) CY1125460T1 (lt)
DK (1) DK3555097T3 (lt)
EC (1) ECSP19042688A (lt)
ES (1) ES2922379T3 (lt)
HR (1) HRP20220885T1 (lt)
HU (1) HUE059274T2 (lt)
IL (1) IL267275B (lt)
JO (1) JOP20190143B1 (lt)
LT (1) LT3555097T (lt)
MD (1) MD3555097T2 (lt)
MX (2) MX391936B (lt)
MY (1) MY196260A (lt)
NI (1) NI201900060A (lt)
NZ (1) NZ795615A (lt)
PE (1) PE20191105A1 (lt)
PH (1) PH12019501254A1 (lt)
PL (1) PL3555097T3 (lt)
PT (1) PT3555097T (lt)
RS (1) RS63500B1 (lt)
SA (1) SA519402216B1 (lt)
SI (1) SI3555097T1 (lt)
SM (1) SMT202200326T1 (lt)
TW (1) TWI777997B (lt)
UA (1) UA125042C2 (lt)
WO (1) WO2018112379A1 (lt)
ZA (1) ZA201904615B (lt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114656464B (zh) 2016-10-24 2024-10-15 阿斯利康(瑞典)有限公司 可用于治疗癌症的6,7,8,9-四氢-3H-吡唑并[4,3-f]异喹啉衍生物
WO2018112379A1 (en) 2016-12-16 2018-06-21 Janssen Pharmaceutica Nv Small molecule inhibitors of the jak family of kinases
JOP20190144A1 (ar) * 2016-12-16 2019-06-16 Janssen Pharmaceutica Nv إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز
TWI831738B (zh) 2016-12-16 2024-02-11 美商瑞塔醫藥有限責任公司 用於抑制RORγ及其他用途的嘧啶三環烯酮衍生物
WO2018138303A1 (en) 2017-01-30 2018-08-02 Astrazeneca Ab Estrogen receptor modulators
JP7498122B2 (ja) 2018-06-15 2024-06-11 リアタ ファーマシューティカルズ インコーポレイテッド IL-17およびRORγの阻害用のピラゾール化合物およびイミダゾール化合物
TW202016110A (zh) * 2018-06-15 2020-05-01 比利時商健生藥品公司 Jak激酶家族之小分子抑制劑
EP3810141A1 (en) 2018-06-20 2021-04-28 Reata Pharmaceuticals, Inc. Cysteine-dependent inverse agonists of nuclear receptors ror-gamma/ror-gamma-t and methods of treating diseases or disorders therewith
WO2020216936A1 (en) 2019-04-24 2020-10-29 Janssen Pharmaceutica Nv Non-clinical liquid formulations of pan-jak inhibitor
AU2020289149B2 (en) * 2019-06-06 2023-05-11 Hangzhou Highlightll Pharmaceutical Co., Ltd. Synthesis method of furoimidazopyridine compound, crystal form of furoimidazopyridine compound, and crystal form of salt thereof
CN110483514B (zh) * 2019-09-16 2022-06-14 启元生物(杭州)有限公司 一种氰基取代的环肼衍生物及其应用
CN114761013A (zh) 2019-09-27 2022-07-15 迪斯克医药公司 治疗骨髓纤维化和相关病症的方法
ES3037893T3 (en) 2020-02-21 2025-10-07 Zhuhai United Laboratories Co Ltd Crystalline form of jak inhibitor and application thereof
US20210330653A1 (en) 2020-04-24 2021-10-28 Astrazeneca Ab Dosage Regimen for the Treatment of Cancer
CA3179912A1 (en) 2020-04-24 2021-10-28 Astrazeneca Ab Pharmaceutical formulations
KR20230012539A (ko) 2020-05-13 2023-01-26 디스크 메디슨, 인크. 골수섬유증을 치료하기 위한 항-헤모주벨린 (hjv) 항체
CN116925077A (zh) * 2020-09-08 2023-10-24 一又生物(上海)有限公司 吡啶并环类化合物及其制备方法、中间体、组合物和应用
CA3213134A1 (en) 2021-03-11 2022-09-15 Janssen Pharmaceutica Nv Lorpucitinib for use in the treatment of jak mediated disorders
CN113292561A (zh) * 2021-05-22 2021-08-24 中国药科大学 一种二吡咯并吡啶结构的化合物、制备方法和医药用途
CN114432317A (zh) * 2021-05-31 2022-05-06 广州嘉越医药科技有限公司 吡咯并嘧啶类化合物的用途
CN113861194B (zh) * 2021-11-10 2022-07-05 英维沃化工科技(广州)有限公司 一种含吡咯并吡啶双酰胺咪唑类化合物及其制备方法和应用

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6080747A (en) 1999-03-05 2000-06-27 Hughes Institute JAK-3 inhibitors for treating allergic disorders
MXPA01010821A (es) 1999-04-23 2003-09-04 Smithkline Beecham Plc Forma poliformica de sal de acido maleico de 5-[4-[2 -(n-metil -n-(2- piridil) amino ) etoxi] bencil ] tiazolidin-2, 4-diona.
AR033485A1 (es) 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
AU2003249658A1 (en) 2002-05-31 2003-12-19 Schering Corporation Xanthine phosphodiesterase v inhibitor polymorphs
GB0319935D0 (en) 2003-08-26 2003-09-24 Cipla Ltd Polymorphs
US7737279B2 (en) 2005-05-10 2010-06-15 Bristol-Myers Squibb Company 1,6-dihydro-1,3,5,6-tetraaza-as-indacene based tricyclic compounds and pharmaceutical compositions comprising same
MX2008000384A (es) 2005-07-01 2008-03-07 Wyeth Corp Formas cristalinas de 4-[(2,4-dicloro-5-metoxifenil)amino]-6-metox i-7-[3-(4-metil-1-piperazinil)propoxi]-3-quinolinocarbonitrilo y metodos para su preparacion.
EP2251341A1 (en) 2005-07-14 2010-11-17 Astellas Pharma Inc. Heterocyclic Janus kinase 3 inhibitors
WO2007007919A2 (en) * 2005-07-14 2007-01-18 Astellas Pharma Inc. Heterocyclic janus kinase 3 inhibitors
TW201612182A (en) 2008-06-10 2016-04-01 Abbvie Inc Novel tricyclic compounds
KR101669311B1 (ko) 2009-09-03 2016-10-25 브리스톨-마이어스 스큅 컴퍼니 Jak2 억제제, 및 골수증식성 질환 및 암의 치료를 위한 그의 용도
JP2011066747A (ja) * 2009-09-18 2011-03-31 Panasonic Corp 弾性波フィルタ
SG10201407976UA (en) 2009-12-01 2015-01-29 Abbvie Inc Novel tricyclic compounds
KR20120102724A (ko) 2009-12-01 2012-09-18 아보트 러보러터리즈 신규한 트리사이클릭 화합물
EP2523957A1 (en) 2010-01-12 2012-11-21 F. Hoffmann-La Roche AG Tricyclic heterocyclic compounds, compositions and methods of use thereof
AU2011214254B2 (en) 2010-02-10 2016-06-09 Genon Biotechnologies Oy Dual activity kinase domains and uses thereof
WO2013007765A1 (en) * 2011-07-13 2013-01-17 F. Hoffmann-La Roche Ag Fused tricyclic compounds for use as inhibitors of janus kinases
GB201212081D0 (en) 2012-07-06 2012-08-22 Kalvista Pharmaceuticals Ltd New polymorph
WO2014123167A1 (ja) 2013-02-08 2014-08-14 日産化学工業株式会社 3環性ピロロピリジン化合物及びjak阻害剤
EP2924026A1 (en) 2014-03-28 2015-09-30 Novartis Tiergesundheit AG Aminosulfonylmethylcyclohexanes as JAK inhibitors
CN106459050B (zh) 2014-05-14 2019-02-26 日产化学株式会社 三环化合物以及jak抑制剂
EP3303348B1 (en) 2015-05-28 2019-08-07 Theravance Biopharma R&D IP, LLC Naphthyridine compounds as jak kinase inhibitors
EP3371332A4 (en) 2015-11-04 2019-04-03 Mayo Foundation for Medical Education and Research METHOD AND MATERIALS FOR TREATING AUTOIMMUNE DISEASES
JOP20190053A1 (ar) 2016-09-23 2019-03-21 Novartis Ag مركبات أزا إندازول للاستخدام في إصابات الأوتار و/ أو الرباط
CN114656464B (zh) 2016-10-24 2024-10-15 阿斯利康(瑞典)有限公司 可用于治疗癌症的6,7,8,9-四氢-3H-吡唑并[4,3-f]异喹啉衍生物
LT3555064T (lt) 2016-12-16 2023-01-10 Pfizer Inc. Glp-1 receptoriaus agonistai ir jų naudojimas
EP3528645A1 (en) 2016-12-16 2019-08-28 Société des Produits Nestlé S.A. Oligosaccharides for flavour generation
WO2018112379A1 (en) 2016-12-16 2018-06-21 Janssen Pharmaceutica Nv Small molecule inhibitors of the jak family of kinases
EP3555105B1 (en) 2016-12-16 2020-10-28 Eli Lilly and Company 7-phenylethylamino-4h-pyrimido[4,5-d][1,3]oxazin-2-one compounds as mutant idh1 and idh2 inhibitors
JOP20190144A1 (ar) 2016-12-16 2019-06-16 Janssen Pharmaceutica Nv إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز
KR20190092539A (ko) 2016-12-16 2019-08-07 바스프 에스이 살충 화합물
RU2019125177A (ru) 2017-01-11 2021-02-15 Лео Фарма А/С Новые производные амино-имидазопиридина в качестве ингибиторов янус-киназы и их фармацевтическое применение
WO2018138303A1 (en) 2017-01-30 2018-08-02 Astrazeneca Ab Estrogen receptor modulators
CN110831600B (zh) 2017-04-21 2023-10-17 医肯纳肿瘤学公司 吲哚ahr抑制剂和其用途
CN106881892B (zh) 2017-04-27 2020-10-16 双钱集团(江苏)轮胎有限公司 一种轮胎生产用生胎转移系统
TW202016110A (zh) 2018-06-15 2020-05-01 比利時商健生藥品公司 Jak激酶家族之小分子抑制劑
WO2020216936A1 (en) 2019-04-24 2020-10-29 Janssen Pharmaceutica Nv Non-clinical liquid formulations of pan-jak inhibitor

Also Published As

Publication number Publication date
PL3555097T3 (pl) 2022-10-17
US11059823B2 (en) 2021-07-13
CY1125460T1 (el) 2025-05-09
SMT202200326T1 (it) 2022-09-14
MX391936B (es) 2025-03-21
US20190177321A1 (en) 2019-06-13
AU2017377069B2 (en) 2020-07-23
KR20190086779A (ko) 2019-07-23
SA519402216B1 (ar) 2022-10-02
AU2020257068A1 (en) 2020-11-19
NI201900060A (es) 2020-03-16
WO2018112379A1 (en) 2018-06-21
CO2019006200A2 (es) 2019-06-28
DK3555097T3 (da) 2022-07-25
MY196260A (en) 2023-03-24
UA125042C2 (uk) 2021-12-29
ECSP19042688A (es) 2019-06-30
US20210340143A1 (en) 2021-11-04
PH12019501254A1 (en) 2020-01-20
CN110088105A (zh) 2019-08-02
JOP20190143A1 (ar) 2019-06-13
HRP20220885T1 (hr) 2022-12-09
NZ795615A (en) 2025-11-28
EP3555097A1 (en) 2019-10-23
CA3046965A1 (en) 2018-06-21
US20190185474A1 (en) 2019-06-20
IL267275A (en) 2019-08-29
MX2019007073A (es) 2019-10-15
US10487083B2 (en) 2019-11-26
AU2022204240A1 (en) 2022-07-07
US10364246B2 (en) 2019-07-30
US12202831B2 (en) 2025-01-21
ZA201904615B (en) 2021-05-26
PT3555097T (pt) 2022-09-22
NZ755404A (en) 2024-10-25
KR102352462B1 (ko) 2022-01-17
AU2017377069A1 (en) 2019-06-20
TW201831180A (zh) 2018-09-01
TWI777997B (zh) 2022-09-21
MD3555097T2 (ro) 2022-12-31
CN110088105B (zh) 2022-03-18
RS63500B1 (sr) 2022-09-30
IL267275B (en) 2021-07-29
US10294226B2 (en) 2019-05-21
HUE059274T2 (hu) 2022-11-28
JP2020502113A (ja) 2020-01-23
US20180170931A1 (en) 2018-06-21
ES2922379T3 (es) 2022-09-14
US20190177322A1 (en) 2019-06-13
JOP20190143B1 (ar) 2023-09-17
EP4086256A1 (en) 2022-11-09
BR112019011968A2 (pt) 2019-11-05
SI3555097T1 (sl) 2022-09-30
CR20190282A (es) 2019-08-21
PE20191105A1 (es) 2019-08-23
EP3555097B1 (en) 2022-06-15
JP7291077B2 (ja) 2023-06-14
AU2022204240B2 (en) 2023-10-05
CL2019001626A1 (es) 2019-10-04
JP2023071709A (ja) 2023-05-23
MX2022004474A (es) 2023-08-15
JP7493068B2 (ja) 2024-05-30

Similar Documents

Publication Publication Date Title
LT3555097T (lt) Imidazo[4,5-d]pirolo[2,3-b]piridino junginiai kaip janus kinazės inhibitoriai
IL277576A (en) Mutated pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors
IL265918B (en) Converted pyrazolo[1,5–a]pyridine compounds as ret kinase inhibitors
HUE053067T2 (hu) Helyettesített pirazolo[1,5-A]piridin vegyületek, mint RET kináz inhibitorok
DK3478682T3 (da) [1,2,4]triazolo[1,5-a]pyridinylsubstituerede indolforbindelser
PT3371185T (pt) Derivados de 4,5,6,7-tetrahidro-1h-imidazo[4,5-c]piridina e 1,4,5,6,7,8-hexahidroimidazo[4,5-d]azepina como inibidores de janus quinase
PT3712152T (pt) Derivados de 4,5,6,7-tetrahidro-1h-imidazo[4,5-c]piridina e 1,4,5,6,7,8-hexahidroimidazo[4,5-d]azepina como inibidores de janus quinase
HUE054371T2 (hu) 4,6-szubsztituált pirazolo[l,5-A]pirazinok mint janus kináz inhibitorok
DK3478681T3 (da) 1h-pyrazolo[4,3-b]pyridiner som pde1-inhibitorer
EP3452481A4 (en) IMIDAZO [1,2-B] SUBSTITUTED PYRIDAZINES, IMIDAZO [1,5-B] SUBSTITUTED PYRIDAZINES, RELATED COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL CONDITIONS
EP3508487A4 (en) PYRAZOLO [1,5-A] PYRIMIDINE COMPOUND
MA46463A (fr) Composés de pyrazolo[1,5-a]pyridine substitués en tant qu'inhibiteurs de la kinase ret